Viridian’s Positive Chronic TED Data Expected to Lead to BLA Filing in Second Half of 2025
Company Reports Positive Phase 3 Study Results for Chronic Thyroid Eye Disease Treatment Introduction The pharmaceutical company recently announced positive results from the phase 3 THRIVE-2 study evaluating the effectiveness of veligrotug in treating patients with chronic thyroid eye disease (TED). This news has positioned the company to file a Biologics License Application (BLA) in…